Radiopharmaceutical · Kills target cells, directed at fibroblast activation protein (FAP) · developed by Immunome
177Lu-IM-3050 is a radioconjugate of IM-3050, a small molecule ligand that binds fibroblast activation protein (FAP), a cell surface protein overexpressed on cancer-associated fibroblasts and certain tumor cells. Its albumin-binding domain extends circulation time, and the attached lutetium-177 beta emitter delivers cytotoxic radiation to FAP-expressing cells. It is being studied in solid malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07505771 | Phase 1 | Solid Malignancies | Recruiting | IMNM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Malignancies
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMNM page.
See IMNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMNM catalysts and pipeline →